RETATRUTIDE – 10mg

Description

Retatrutide is a synthetic peptide in the class of multi-receptor incretin agonists, engineered to engage three related receptors: GLP-1R, GIPR and GCGR. These are class B G protein-coupled receptors within the incretin signalling system, a hormone network coordinating metabolic communication between the pancreas, gastrointestinal tract, liver and brain.

Researchers can buy retatrutide 10 mg from Dragon Laboratories. This is a high-purity research peptide independently tested by accredited laboratories for peptide identity, purity, and analytical consistency. Certificates of Analysis are available for every product batch to give researchers full transparency, traceability, and quality documentation as expected for advanced incretin and metabolic research compounds.

Retatrutide Structure and Design

Structurally, retatrutide is built on a GIP peptide backbone with targeted substitutions that introduce cross-reactivity at the GLP-1 and glucagon receptors. Several key modifications contribute to its receptor activity and pharmacokinetic profile:

• Aib² (2-aminoisobutyric acid) at position 2 increases resistance to degradation by dipeptidyl peptidase-4 (DPP-4), contributing to the peptide’s prolonged biological activity.
• αMeLeu¹³ (α-methylleucine) at position 13 enhances activity at both the GIP and glucagon receptors while helping maintain balanced multi-receptor agonism.
• Aib²⁰ (2-aminoisobutyric acid) at position 20 contributes to the peptide’s pharmacokinetic properties and supports its GIP receptor activity.
• C-terminal amidation reduces susceptibility to degradation by carboxypeptidases, improving overall peptide stability.

The molecule carries a C20 fatty diacid conjugated through a gamma-glutamate and AEEA linker at a lysine side chain. This enables reversible albumin binding, which drives the long circulating half-life of roughly six days and underpins the once-weekly schedule used across its clinical programme.

The third receptor is what separates retatrutide from tirzepatide. Dual agonists engage GIP and GLP-1. Adding glucagon receptor activity brings in a pathway associated with energy expenditure and hepatic fat oxidation, giving researchers a tool for studying multi-pathway metabolic regulation rather than appetite and glycaemic signalling alone.